U.S. Markets closed
  • S&P Futures

    3,628.25
    -8.25 (-0.23%)
     
  • Dow Futures

    29,760.00
    -114.00 (-0.38%)
     
  • Nasdaq Futures

    12,278.00
    +20.50 (+0.17%)
     
  • Russell 2000 Futures

    1,845.20
    -7.80 (-0.42%)
     
  • Crude Oil

    45.11
    -0.42 (-0.92%)
     
  • Gold

    1,780.20
    -7.90 (-0.44%)
     
  • Silver

    22.33
    -0.31 (-1.39%)
     
  • EUR/USD

    1.1970
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3335
    +0.0021 (+0.1560%)
     
  • USD/JPY

    103.8800
    -0.2050 (-0.1970%)
     
  • BTC-USD

    18,462.01
    +110.56 (+0.60%)
     
  • CMC Crypto 200

    364.39
    +26.90 (+7.97%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,666.91
    +22.20 (+0.08%)
     

Have Insiders Been Selling Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares?

Simply Wall St

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look at whether insiders have been buying or selling shares in Theravance Biopharma, Inc. (NASDAQ:TBPH).

What Is Insider Selling?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, rules govern insider transactions, and certain disclosures are required.

We don't think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

Check out our latest analysis for Theravance Biopharma

The Last 12 Months Of Insider Transactions At Theravance Biopharma

In the last twelve months, the biggest single sale by an insider was when the insider, Sharathchandra Hegde, sold US$223k worth of shares at a price of US$25.06 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$19.07. So it may not tell us anything about how insiders feel about the current share price.

Over the last year, we note insiders sold 13033 shares worth US$305k. In the last year Theravance Biopharma insiders didn't buy any company stock. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGM:TBPH Recent Insider Trading, October 2nd 2019
NasdaqGM:TBPH Recent Insider Trading, October 2nd 2019

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of Theravance Biopharma

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Theravance Biopharma insiders own 6.5% of the company, worth about US$70m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Theravance Biopharma Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. Still, the insider transactions at Theravance Biopharma in the last 12 months are not very heartening. But we do like the fact that insiders own a fair chunk of the company. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.